Trevi Therapeutics reports Q1 net loss $13.2M; cash runway extended to 2030 after $162M offering

Trevi Therapeutics, Inc.

2026-Q1 EPS reported -$0.09

Net loss of $13.2M in Q1 2026 vs $10.3M YoY; R&D expenses $9.9M, G&A $5.0M.
Cash, equivalents and marketable securities $171.8M at March 31; April offering net ~$162M.
FDA alignment on Phase 3 plan for Haduvio in IPF-related chronic cough; first Phase 3 starts Q2 2026.
Phase 2b in refractory chronic cough starts Q2 2026; Phase 2b in non-IPF ILD cough starts H2 2026.
European patent granted for nalbuphine ER in IPF cough, expiration 2039.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Trevi Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.

Period: the quarter ended March 31, 2026
Net income: Net loss: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10
Result: reported results

Exact text from the filing

For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.3 million in the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.